Multifunctional Nanoparticles Inhibit HSPs Expression and Improve Pyroptosis Through ROS Amplification in Mild Photothermal Therapy of Oral Squamous Cell Carcinoma

Why It Matters

By coupling ROS‑induced pyroptosis with heat‑shock protein inhibition, the platform delivers potent anticancer effects at lower temperatures, reducing collateral damage and addressing a key resistance mechanism in OSCC.

Key Takeaways

• Folate-modified PDA nanoparticles loaded with CuO2 release ROS.
• ROS triggers GSDMD palmitoylation, enhancing pyroptosis in OSCC.
• Elevated ROS suppresses HSP expression, enabling mild photothermal therapy.
• Combined pyroptosis and MPTT markedly reduces tumor growth.
• Strategy offers targeted, low‑temperature cancer treatment.

Pulse Analysis

Oral squamous cell carcinoma remains a leading cause of head‑and‑neck cancer mortality, in part because conventional therapies often trigger heat‑shock protein (HSP) up‑regulation that shields tumor cells from thermal and oxidative stress. HSPs act as molecular chaperones, stabilizing proteins and dampening programmed cell death pathways, which limits the efficacy of photothermal approaches that rely on high temperatures. Moreover, many OSCC lesions exhibit an immunosuppressive microenvironment that hampers immune‑mediated clearance. Addressing both the thermal resistance and the need for immunogenic cell death has become a priority for researchers seeking more precise, less toxic treatments.

The newly reported PDCF nanoparticles integrate folate‑acid targeting, polydopamine photothermal conversion, and copper peroxide–driven ROS generation into a single platform. Upon mild laser irradiation, the copper peroxide decomposes, flooding the cytosol with hydrogen peroxide that rapidly converts to hydroxyl radicals. These ROS not only oxidatively damage cellular components but also catalyze the palmitoylation of Gasdermin D, a prerequisite for its cleavage into the pore‑forming GSDMD‑N fragment that drives pyroptosis. Simultaneously, the oxidative burst suppresses HSP expression, lowering the thermal threshold needed for effective photothermal ablation.

The convergence of amplified pyroptosis and subdued HSP defenses yields a synergistic anticancer effect, achieving pronounced tumor shrinkage in animal models while operating at temperatures that spare surrounding healthy tissue. This dual‑mode strategy could reshape OSCC management by providing a targeted, immunogenic therapy that also mitigates the side‑effects associated with high‑intensity laser treatments. Future work will need to validate long‑term safety, scale up manufacturing, and explore combination with checkpoint inhibitors to fully exploit the immune activation inherent to pyroptotic cell death. If successful, the platform may extend to other HSP‑rich malignancies.